Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation
- PMID: 9180187
- DOI: 10.1086/516480
Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation
Abstract
To investigate the incidence, risk factors, and outcome of Aspergillus infections among marrow transplant recipients, records from 2496 patients were reviewed, and 214 patients had Aspergillus organisms identified. Of these, 158 had invasive aspergillosis, 44 were colonized, and 12 had contaminated cultures. The incidence of invasive aspergillosis increased from 5.7% to 11.2% during the study. The onset of infection was bimodal, peaking 16 and 96 days after transplant. For patients within 40 days after transplant, underlying disease, donor type, season, and transplant outside of laminar air flow rooms were associated with significant risk for invasive aspergillosis. For patients >40 days after transplant, age, underlying disease, donor type, graft-versus-host disease, neutropenia, and corticosteroid use were associated with increased risk of aspergillosis. Only 31% of infected patients were neutropenic at the time of diagnosis. The risk factors for aspergillosis depend on the time after marrow transplant and include both host and environmental characteristics.
Comment in
-
Prevention of aspergillosis in bone marrow transplantation.J Infect Dis. 1998 Jun;177(6):1775-6. doi: 10.1086/517421. J Infect Dis. 1998. PMID: 9607875 No abstract available.
Similar articles
-
Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital.Bone Marrow Transplant. 2002 Jan;29(1):15-9. doi: 10.1038/sj.bmt.1703332. Bone Marrow Transplant. 2002. PMID: 11840139
-
Aspergillus infections in bone marrow transplant recipients.Bone Marrow Transplant. 1987 Aug;2(2):175-81. Bone Marrow Transplant. 1987. PMID: 3332165
-
Invasive mold infections in allogeneic bone marrow transplant recipients.Clin Infect Dis. 2001 May 1;32(9):1319-24. doi: 10.1086/319985. Epub 2001 Apr 13. Clin Infect Dis. 2001. PMID: 11303267
-
[Epidemiology of and risk factors for invasive aspergillosis in nonneutropenic patients].Rev Mal Respir. 2008 Feb;25(2):139-53. doi: 10.1016/s0761-8425(08)71512-2. Rev Mal Respir. 2008. PMID: 18449076 Review. French.
-
Epidemiology of invasive aspergillosis and risk factors in non neutropaenic patients.Rev Mal Respir. 2010 Oct;27(8):e34-46. doi: 10.1016/j.rmr.2010.01.004. Epub 2010 May 15. Rev Mal Respir. 2010. PMID: 20965392 Review.
Cited by
-
Posaconazole-Loaded Leukocytes as a Novel Treatment Strategy Targeting Invasive Pulmonary Aspergillosis.J Infect Dis. 2017 Jun 1;215(11):1734-1741. doi: 10.1093/infdis/jiw513. J Infect Dis. 2017. PMID: 27799353 Free PMC article.
-
Emergence of opportunistic mould infections in the hematopoietic stem cell transplant patient.Curr Infect Dis Rep. 2006 Nov;8(6):434-41. doi: 10.1007/s11908-006-0017-5. Curr Infect Dis Rep. 2006. PMID: 17064636
-
Detection of sputum Aspergillus galactomannan for diagnosis of invasive pulmonary aspergillosis in haematological patients.Int J Hematol. 2009 Nov;90(4):463-470. doi: 10.1007/s12185-009-0429-8. Epub 2009 Oct 20. Int J Hematol. 2009. PMID: 19838867
-
A polymerase chain reaction enzyme immunoassay for diagnosing infection caused by Aspergillus fumigatus.J Clin Pathol. 1999 Jun;52(6):419-23. doi: 10.1136/jcp.52.6.419. J Clin Pathol. 1999. PMID: 10562808 Free PMC article.
-
Multidimensional volumetric imaging of pulmonary infiltrates for measuring therapeutic response to antifungal therapy in experimental invasive pulmonary aspergillosis.Antimicrob Agents Chemother. 2006 Apr;50(4):1510-7. doi: 10.1128/AAC.50.4.1510-1517.2006. Antimicrob Agents Chemother. 2006. PMID: 16569871 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
